A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsA Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sponsor:

Sensei Biotherapeutics, Inc.

Code:

NCT05864144

Conditions

Solid Tumor, Adult

Advanced Solid Tumor

Head and Neck Cancer

Breast Cancer

Colon Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SNS-101 (anti-VISTA)

Cemiplimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-01. This information was provided to ClinicalTrials.gov by Sensei Biotherapeutics, Inc. on 2025-03-25.